STEMI - ST Elevation Myocardial Infarction Clinical Trial
Official title:
Neutrophil Gelatinase-associated Lipocalin (NGAL) and Its Association With the No-reflow Phenomenon in ST-elevation Myocardial Infarction
The aim of this study is to investigate the association between NGAL plasma levels in ST-elevation myocardial infarction and the no-reflow phenomenon, adverse events during hospitalization and at 30-day follow-up.
Neutrophil Gelatinase-associated Lipocalin (NGAL) is a acute phase protein which is elevated in conditions like acute kidney injury and myocardial infarction. When a coronary artery is occluded, detrimental changes occur in myocardial vessels. After relief of the occlusion, blood flow to the heart may still be impeded, a phenomenon known as "no-reflow". Data is lacking on factors associated with early detection of patients at risk for this phenomenon, and early stratification of this group seems vital since the no-reflow phenomenon is associated with worse outcomes. The investigators hypothesized that there might be an association between higher NGAL levels and the occurrence of no-flow findings, and that NGAL might serve as a marker of worse prognosis in this population. The investigators also hypothesized that NGAL levels might serve as a marker of early acute kidney injury and that there might be specific patterns of NGAL levels over time in different subsets of patients. The aim of the study is to determine the association between NGAL levels at admission and during the first days after a ST-elevation myocardial infarction, the occurrence of the no-reflow phenomenon, the extent of myocardial damage ascertained by cardiac imaging techniques (echocardiography and cardiac resonance imaging). Data regarding patients' clinical, laboratory, electrocardiogram, coronary angiography and percutaneous coronary intervention, in-hospital and 30-day follow-up after discharge will be recorded. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06013813 -
Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI
|
N/A | |
Terminated |
NCT04542889 -
Coronary Microcirculation Assessment After Primary Angioplasty in Myocardial Infarction
|
N/A | |
Recruiting |
NCT04951856 -
Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI
|
Phase 4 | |
Terminated |
NCT04459299 -
CorPath GRX STEMI Study
|
||
Recruiting |
NCT05557019 -
Semi Occlusion of the Coronary Sinus as an Adjunct to PCI in STEMI Patients, FIH Clinical Study
|
N/A | |
Completed |
NCT03527940 -
Prognostic Markers of Patients With STEMI
|
||
Not yet recruiting |
NCT03182855 -
Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI
|
Phase 4 | |
Not yet recruiting |
NCT03266289 -
Evaluation of Short Term Outcome of Different Bifurcation Stenting Techniques at Assuit University Cath. Lab
|
N/A | |
Withdrawn |
NCT04566289 -
Observational Registry to Evaluate Real World Usage of PiCSO Impulse System in STEMI Patients as Part of Post-marketing Surveillance
|
||
Completed |
NCT04289012 -
HELicobacter Pylori Screening in Patients With Acute Myocardial Infarction Pilot Study
|
N/A | |
Not yet recruiting |
NCT04185077 -
Bivalirudin in Late PCI for Oatients With STEMI
|
Phase 4 | |
Completed |
NCT03609346 -
Asian Registry of the BioFreedom Stent for STEMI Patients
|
||
Recruiting |
NCT05107076 -
Effect of PPCI on Diastolic Function & Levels of Galactin-3 in Patients With STEMI
|
||
Recruiting |
NCT02998853 -
Non Culprit Functional Evaluation With 3D Angio QFR in STEMI PCI Procedure
|
N/A | |
Completed |
NCT03677180 -
National Cardiogenic Shock Initiative
|
||
Completed |
NCT03507777 -
ILUMIEN IV: OPTIMAL PCI
|
N/A | |
Recruiting |
NCT03863327 -
EKG Criteria and Identification of Acute Coronary Occlusion
|
||
Completed |
NCT03070496 -
Multicenter Cohort of STEMI Patients
|
N/A | |
Active, not recruiting |
NCT03874338 -
CLEAR SYNERGY Neutrophil Substudy
|
||
Withdrawn |
NCT05497011 -
A Study to Evaluate the Safety and Efficacy of PiCSO in Anterior STEMI Patients
|
N/A |